Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Aly

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
JAMA Network Open|February 2, 2024
Risk of Venous Thromboembolic Events After Surgery for CancerJohan Björklund, Juhana Rautiola, Renata Zelic, et al.
Annals of Surgical Oncology|December 13, 2023
Risk of Postoperative Ischemic Stroke and Myocardial Infarction in Patients Operated for CancerJuhana Rautiola, Johan Björklund, Renata Zelic, et al.
World Journal of Urology|February 5, 2026
Time to BCR and cancer-specific mortality after radiotherapy or prostatectomy: implications for risk stratification and follow-upFrancesco Pellegrino, Ralph Grauer, Ugo Giovanni Falagario, et al.
Scandinavian Journal of Urology|June 7, 2021
Real world treatment utilization patterns in patients with castration-resistant prostate cancerHari T Vigneswaran, Anna Warnqvist, Therese M L Andersson, et al.
European Urology|October 17, 2025
Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 TrialHari T Vigneswaran, Thorgerdur Palsdottir, Chiara Micoli, et al.
European Urology Oncology|June 22, 2025
Epidemiology of High-risk Biochemical Recurrence After Primary Prostate Cancer TreatmentUgo Giovanni Falagario, Francesco Pellegrino, Lars Björnebo, et al.
Cancer|August 17, 2025
Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancerUgo Giovanni Falagario, Francesco Pellegrino, Ahmad Abbadi, et al.
European Urology|October 4, 2025
Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled TrialMarkus Graefen, Fabian Falkenbach, Tobias Maurer, et al.
BMC Medical Genomics|December 18, 2010
Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expressionJeff A Klomp, David Petillo, Natalie M Niemi, et al.
European Urology Oncology|December 28, 2023
Assessing the Impact of Positive Surgical Margins on Mortality in Patients Who Underwent Robotic Radical Prostatectomy: 20 Years' Report from the EAU Robotic Urology Section Scientific Working GroupFrancesco Pellegrino, Ugo Giovanni Falagario, Sophie Knipper, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
JAMA Network Open|February 2, 2024
Risk of Venous Thromboembolic Events After Surgery for CancerJohan Björklund, Juhana Rautiola, Renata Zelic, et al.
Annals of Surgical Oncology|December 13, 2023
Risk of Postoperative Ischemic Stroke and Myocardial Infarction in Patients Operated for CancerJuhana Rautiola, Johan Björklund, Renata Zelic, et al.
World Journal of Urology|February 5, 2026
Time to BCR and cancer-specific mortality after radiotherapy or prostatectomy: implications for risk stratification and follow-upFrancesco Pellegrino, Ralph Grauer, Ugo Giovanni Falagario, et al.
Scandinavian Journal of Urology|June 7, 2021
Real world treatment utilization patterns in patients with castration-resistant prostate cancerHari T Vigneswaran, Anna Warnqvist, Therese M L Andersson, et al.
European Urology|October 17, 2025
Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 TrialHari T Vigneswaran, Thorgerdur Palsdottir, Chiara Micoli, et al.
European Urology Oncology|June 22, 2025
Epidemiology of High-risk Biochemical Recurrence After Primary Prostate Cancer TreatmentUgo Giovanni Falagario, Francesco Pellegrino, Lars Björnebo, et al.
Cancer|August 17, 2025
Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancerUgo Giovanni Falagario, Francesco Pellegrino, Ahmad Abbadi, et al.
European Urology|October 4, 2025
Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled TrialMarkus Graefen, Fabian Falkenbach, Tobias Maurer, et al.
BMC Medical Genomics|December 18, 2010
Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expressionJeff A Klomp, David Petillo, Natalie M Niemi, et al.
European Urology Oncology|December 28, 2023
Assessing the Impact of Positive Surgical Margins on Mortality in Patients Who Underwent Robotic Radical Prostatectomy: 20 Years' Report from the EAU Robotic Urology Section Scientific Working GroupFrancesco Pellegrino, Ugo Giovanni Falagario, Sophie Knipper, et al.
Pageof 9